{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-024969","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.460876+00:00","generated_at":"2026-06-17T08:09:00.835079+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Unicycive reports 2022 net loss of $18.1M, cash $0.5M; closes $30M fundraise; NDA on track for mid-2023","bullets":["Net loss for 2022 was $18.1M ($1.20/sh) vs $10.0M ($0.86/sh) in 2021.","Cash and equivalents $0.5M at Dec 31, 2022; closed $30M private placement with up to $130M total.","Renazorb pivotal BE study met primary endpoint; NDA submission on track for mid-2023.","Exclusive license with Lotus Pharma for Renazorb in South Korea.","R&D expenses $12.4M (up 103% YoY) driven by $6.5M in development services."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-024969","json":"https://secwatch.observer/filing/0001213900-23-024969.json","markdown":"https://secwatch.observer/filing/0001213900-23-024969.md","text":"https://secwatch.observer/filing/0001213900-23-024969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023024969/0001213900-23-024969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023024969/ea176065-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:09:00.835079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d522bc522dcece3bc58f337af4c34d1c0efc6c88","claim":"Unicycive Therapeutics, Inc. reported financial results for full year ended December 31, 2022.","evidence_excerpt":"On March 31, 2023, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2022 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023024969/0001213900-23-024969-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}